ENG/中
老虎證券
行情
交易
收費
下載
優惠與活動
幫助
TigerAI
學堂
期權訓練營
投資學堂
機構
財富及資產管理人
自營交易機構
介紹經紀商
三方服務商
股權激勵
關於
關於我們
媒體報道
獎項與榮譽
登入
立即註冊
Toggle
美股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
iShares Health Innovation Active ETF
33.21
+0.2458
0.75%
盤後：
33.17
-0.0408
-0.12%
16:10 EDT
成交量：
534
成交額：
1.77萬
市值：
1,328.43萬
市盈率：
- -
高：
33.21
開：
33.11
低：
33.11
收：
32.97
52周最高：
34.86
52周最低：
25.79
股本：
40.00萬
流通股本：
40.00萬
量比：
0.27
換手率：
0.13%
股息：
0.08
股息率：
0.25%
淨資產收益率：
--
總資產收益率：
--
市淨率：
--
市盈率(LYR):
- -
資料載入中...
總覽
公司
新聞資訊
公告
強生：RYBREVANT聯合化療在EGFR外顯子20插入突變非小細胞肺癌中實現已報告的最長中位總生存期。
智通财经
·
昨天
強生據報與阿波羅洽談約200億美元骨科業務交易
环球市场播报
·
09/13
傳阿波羅(APO.US)擬接盤強生(JNJ.US)骨科業務 潛在交易估值近200億美元
智通财经
·
09/12
據彭博社報導，阿波羅全球正就收購強生公司骨科業務部門進行談判
路透中文
·
09/12
據彭博社報道，阿波羅全球正就收購強生公司骨科業務部門進行談判
路透中文
·
09/12
據稱阿波羅正在洽談收購強生骨科業務部門。
智通财经
·
09/12
美國食品藥品監督管理局（FDA）批准了Scholar Rock公司的一款治療肌肉無力症的藥物
路透中文
·
09/12
阿斯利康：SERENA-4臨床試驗未達到主要終點。
智通财经
·
09/12
美國股市動態
路透中文
·
09/12
興齊眼藥(300573.SZ)：SQ-23082滴眼液獲批開展臨床試驗
智通财经
·
09/11
興齊眼藥：SQ-23082獲臨床試驗批准，屬2.1類
智通财经
·
09/11
強生（JNJ）漲1.63% 新款雙周拋隱形眼鏡獲CE認證
金吾财讯
·
09/10
翰宇藥業(300199.SZ)：HY3003注射液臨床試驗申請獲受理
智通财经
·
09/10
默沙東帕博利珠單抗三陰性乳腺癌適應症人群擴展在華獲批
智通财经
·
09/10
翰宇藥業：HY3003注射液獲臨床試驗申請受理通知書
智通财经
·
09/10
英硅智能(03696)：公司管線中領先的人工智能驅動候選創新藥物 Rentosertib已在針對特發性肺纖維化的III期臨床試驗中完成首例患者入組
智通财经
·
09/10
拜耳啓動G蛋白偶聯內流整流鉀通道4研究性抑制劑針對心房顫動患者的II期臨床試驗。
智通财经
·
09/09
Leerink Partners上調默克目標價至161美元
格隆汇
·
09/09
石藥集團(01093)：戈舍瑞林緩釋注射液(SYH9102注射液)在中國獲臨床試驗批准
智通财经
·
09/09
石藥集團(01093)：戈舍瑞林緩釋注射液(SYH 9102注射液)在中國獲臨床試驗批准
智通财经
·
09/09
更多
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/hant/stock/BMED/news?page=2"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BMED","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BMED\",,,,,undefined,":{"symbol":"BMED","market":"US","secType":"STK","nameCN":"iShares Health Innovation Active ETF","latestPrice":33.2108,"timestamp":1789416000000,"preClose":32.965,"halted":0,"volume":534,"hourTrading":{"tag":"盘后","latestPrice":33.17,"preClose":33.2108,"latestTime":"16:10 EDT","volume":7,"amount":232.554,"timestamp":1789416603529,"change":-0.0408,"changeRate":-0.001229,"amplitude":0},"delay":0,"changeRate":0.00745639314424376,"floatShares":400000,"shares":400000,"eps":0,"marketStatus":"已收盤","change":0.2458,"latestTime":"09-14 16:00:00 EDT","open":33.11,"high":33.2108,"low":33.11,"amount":17725,"amplitude":0.003058,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789459200000},"marketStatusCode":5,"adr":0,"exchange":"ARCA","adjPreClose":32.965,"sharesOutstanding":360000,"nav":32.890304,"aum":13156121.6,"dividendRate":0.002487,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":33.17,"preClose":33.2108,"latestTime":"16:10 EDT","volume":7,"amount":232.554,"timestamp":1789416603529,"change":-0.0408,"changeRate":-0.001229,"amplitude":0},"volumeRatio":0.273566,"impliedVol":0.068,"impliedVolPercentile":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BMED\",,,,,undefined,":{"symbol":"BMED","floatShares":400000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.273566,"shares":400000,"dividePrice":0.0826,"high":33.2108,"amplitude":0.003058,"preClose":32.965,"low":33.11,"week52Low":25.794,"pbRate":"--","week52High":34.86,"institutionHeld":0,"latestPrice":33.2108,"eps":0,"divideRate":0.002487,"volume":534,"delay":0,"ttmEps":0,"open":33.11,"prevYearClose":30.32,"prevWeekClose":32.965,"prevMonthClose":33.8091,"prevQuarterClose":30.62,"fiveDayClose":34.0304,"twentyDayClose":32.17,"sixtyDayClose":28.4912},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BMED\",params:#limit:5,,,undefined,":[{"date":"2026-06-15","symbol":"BMED","amount":0.08118,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-15","defaultRemindTime":1781530200000,"name":"iShares Health Innovation Active ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-18","payableDate":"2026-06-15","currency":"USD","dateTimestamp":1781496000000,"payDate":"2026-06-18"},{"date":"2023-12-20","symbol":"BMED","amount":0.007207,"announcedDate":"2023-12-20","type":"dividend","market":"US","newRecordDate":"2023-12-21","defaultRemindTime":1703082600000,"name":"BlackRock Future Health ETF","recordDate":"2023-12-27","payableDate":"2023-12-21","currency":"USD","dateTimestamp":1703048400000,"payDate":"2023-12-27"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BMED\",market:\"US\",,,undefined,":[{"executeDate":"2023-12-20","recordDate":"2023-12-21","paymentDate":"2023-12-27","value":0.007207,"currency":"USD"},{"executeDate":"2026-06-15","recordDate":"2026-06-15","paymentDate":"2026-06-18","value":0.08118,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BMED\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BMED\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2667631840","title":"強生：RYBREVANT聯合化療在EGFR外顯子20插入突變非小細胞肺癌中實現已報告的最長中位總生存期。","url":"https://stock-news.laohu8.com/highlight/detail?id=2667631840","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667631840?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 09:46","pubTimestamp":1789350398,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00BLSP4239.USD","LU1894683264.USD","IHE","JDOC","IE0001KFT4U8.USD","IE0002141913.USD","LU1280957306.USD","PJP","LU0820561909.HKD","VHT","LU1674673691.USD","LU0985320562.USD","LU2089984988.USD","BMED","LU2471134523.USD","RXL","IE00BFTCPJ56.SGD","LU1032466523.USD","LU1145028129.USD","LU0053666078.USD","GDOC","FTXH","XLV","FHLC","BK4550","LU2133065610.SGD","IE00BDGV0183.EUR","BK4559","LU1244550494.USD","IE0000B7K699.USD","IYH","BK4533","LU2430703095.HKD","MEDX","LU0426417589.USD","TRUH","LU2471134879.HKD","LU2592432038.USD","LU0072461881.USD","LU0122379950.USD","LU0511384066.AUD","IE00BVYPNV92.GBP","LU1935042991.SGD","BK4568","IE00B3T34201.USD","IE00BGHQF631.EUR","LU0683600562.USD","BK4588","JNJ","IXJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667329689","title":"強生據報與阿波羅洽談約200億美元骨科業務交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2667329689","media":"环球市场播报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667329689?lang=zh_tw&edition=fundamental","pubTime":"2026-09-13 14:27","pubTimestamp":1789280820,"startTime":"0","endTime":"0","summary":"据知情人士消息，阿波罗全球管理公司正洽谈收购强生旗下以DePuy Synthes为主体的骨科业务，交易金额约为200亿美元。知情人士称，强生与阿波罗正在就出售展开谈判，但双方仍可能无法达成交易，强生也可能选择其他买家。强生和阿波罗目前均未公布交易安排。以当前报道的约200亿美元交易金额计算，潜在售价与强生当年的实际收购价格大致相当，但期间业务范围、财务表现和资产构成已经发生变化。此次潜在出售也是强生持续调整业务组合的一部分。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-09-13/doc-inirskha4546532.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU2430703251.USD","IE0009355771.USD","IE00B4R5TH58.HKD","JDOC","LU1778281490.HKD","IE00BFXG1179.USD","LU2129689431.USD","LU0889566641.SGD","LU0640476718.USD","BMED","IHE","MEDX","LU1935042991.SGD","LU1059921491.USD","IE000F7OJYX1.SGD","IE00BVYPNV92.GBP","LU1066053197.SGD","TRUH","LU1732800096.USD","VHT","LU2456880835.USD","LU0792757196.USD","IXJ","LU2089984988.USD","FHLC","IE00B42XCP33.USD","LU0426412945.USD","LU2023250330.USD","IE00B19Z3581.USD","XLV","FTXH","LU2213496289.HKD","LU0820561909.HKD","GDOC","IYH","LU0057025933.USD","PJP","RXL","LU2896262040.SGD","LU0545562505.USD","LU0795875169.SGD","LU1228905540.USD","LU1074936037.SGD","LU1496350502.SGD","LU0795875086.SGD","LU1430594728.SGD","LU2471134523.USD","JNJ","LU0689472784.USD","LU0122379950.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666508051","title":"傳阿波羅(APO.US)擬接盤強生(JNJ.US)骨科業務 潛在交易估值近200億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2666508051","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666508051?lang=zh_tw&edition=fundamental","pubTime":"2026-09-12 11:04","pubTimestamp":1789182275,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，据媒体援引知情人士消息报道，全球另类资产管理公司阿波罗全球管理 正洽谈收购强生的骨科业务部门DePuy Synthes。这笔交易对该业务的估值可能接近200亿美元。强生的骨科业务部门DePuy Synthes主要生产关节植入物和手术器械，2025年创造了93亿美元的收入，但收入增速仅为1.1%。相比之下，强生2025年整体营收同比增长6%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495305.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE000F7OJYX1.SGD","LU1032466523.USD","LU2471134523.USD","PJP","LU2487616109.SGD","LU1057294990.SGD","LU1668664300.SGD","MEDX","FHLC","AAUM","JNJ","IE00B3T34201.USD","XLV","GPZ","LU2129689431.USD","LU2756315318.SGD","LU2471134796.USD","LU0912757837.SGD","LU2112291526.USD","LU2468319806.SGD","BMED","IE000BZT7R73.USD","IE00B775SV38.USD","APO","LU1267930813.SGD","IXJ","LBO","RXL","LU0545562505.USD","LU0345769631.USD","IE0001KFT4U8.USD","IYH","LU0689626769.HKD","LU1506573853.SGD","LU1989771016.USD","IE00B42XCP33.USD","BK4585","LU1244550494.USD","IHE","FTXH","LU1066051498.USD","LU1162221912.USD","VHT","GDOC","IE00BGHQF631.EUR","LU0006061336.USD","TRUH","PRVT","JDOC","LU2602419157.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666778075","title":"據彭博社報導，阿波羅全球正就收購強生公司骨科業務部門進行談判","url":"https://stock-news.laohu8.com/highlight/detail?id=2666778075","media":"路透中文","labels":["corporation","merge","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666778075?lang=zh_tw&edition=fundamental","pubTime":"2026-09-12 06:42","pubTimestamp":1789166537,"startTime":"0","endTime":"0","summary":"据彭博社报导，阿波罗全球正就收购强生公司骨科业务部门进行谈判路透9月11日-据彭博社周五援引消息人士报导，阿波罗全球管理公司（Apollo Global Management，APO.N）正在就收购强生公司（Johnson & JohnsonJNJ.N）旗下骨科业务部门进行磋商，该交易可能使该业务部门的估值接近200亿美元。路透无法立即核实该报导。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nL4T4531JU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IYH","TRUH","GDOC","LU1929549753.HKD","BK4007","LU1066051498.USD","LU1323610961.USD","LU0122379950.USD","IE00BVYPNW00.USD","LU1668664300.SGD","BMED","LU0345770993.USD","IE00BGHQF631.EUR","JNJ","FHLC","LU2750360641.GBP","MEDX","LU1585245621.USD","LU0114720955.EUR","APO","GPZ","LU1778281490.HKD","JDOC","FTXH","LU0234572021.USD","VHT","LU0795875086.SGD","BK4588","LBO","LU1430594728.SGD","PRVT","LU2112291526.USD","LU0203347892.USD","RXL","IHE","PJP","LU2129689514.USD","IXJ","XLV","AAUM","LU2347655156.SGD","IE00BSNM7G36.USD","LU2487616109.SGD","LU0985320562.USD","LU2471134523.USD","LU1228905540.USD","BK4592","LU1032955483.USD","LU1221951046.USD","LU1551013342.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666577802","title":"據彭博社報道，阿波羅全球正就收購強生公司骨科業務部門進行談判","url":"https://stock-news.laohu8.com/highlight/detail?id=2666577802","media":"路透中文","labels":["corporation","merge","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666577802?lang=zh_tw&edition=fundamental","pubTime":"2026-09-12 06:42","pubTimestamp":1789166537,"startTime":"0","endTime":"0","summary":"据彭博社报道，阿波罗全球正就收购强生公司骨科业务部门进行谈判路透9月11日-据彭博社周五援引消息人士报道，阿波罗全球管理公司（Apollo Global Management，APO.N）正在就收购强生公司（Johnson & JohnsonJNJ.N）旗下骨科业务部门进行磋商，该交易可能使该业务部门的估值接近200亿美元。路透无法立即核实该报道。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nL4S4531JU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GPZ","IE000MB6IJN5.SGD","SG9999001176.USD","LU1935042991.SGD","BK4585","VHT","LU1506573853.SGD","LBO","LU0882574055.USD","PJP","IE000M9KFDE8.USD","IE000F7OJYX1.SGD","PRVT","RXL","JNJ","XLV","IE00BKVL7J92.USD","IE00BFXG1179.USD","LU1989771016.USD","LU1196500208.SGD","LU2505996509.AUD","IHE","JDOC","AAUM","IXJ","LU2112291526.USD","BMED","FHLC","LU1894683264.USD","BK4504","GDOC","LU2756315664.SGD","IE00BGHQF631.EUR","LU0203345920.USD","LU1261432733.SGD","FTXH","IYH","LU0820562030.AUD","LU0792757196.USD","LU1043141396.HKD","TRUH","LU0964807845.USD","LU1221951129.SGD","LU1629891620.HKD","LU1228905540.USD","APO","LU0234570918.USD","BK4007","MEDX","LU1059921491.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666657206","title":"據稱阿波羅正在洽談收購強生骨科業務部門。","url":"https://stock-news.laohu8.com/highlight/detail?id=2666657206","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666657206?lang=zh_tw&edition=fundamental","pubTime":"2026-09-12 06:25","pubTimestamp":1789165559,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["FTXH","LU0289739699.SGD","JNJ","LU0795875086.SGD","LU2133065610.SGD","PJP","LU0964807845.USD","XLV","IE00BGHQF631.EUR","LU1221951046.USD","RXL","JDOC","IXJ","IYH","LU0985320562.USD","LU2468319806.SGD","IE00B1BXHZ80.USD","LU1066051498.USD","LU0820562030.AUD","SG9999001440.SGD","GDOC","TRUH","BMED","LU1061106388.HKD","LU0345770993.USD","LU0943347566.SGD","MEDX","LU2487616109.SGD","SG9999001176.USD","LU1244550221.USD","IE0000B7K699.USD","LU0640476718.USD","LU2750360997.AUD","IE00BZ1G4Q59.USD","SGXZ57979304.SGD","SGXZ80539844.SGD","LU0345770308.USD","LU0210536198.USD","LU2756315664.SGD","IE000WAW04H5.SGD","LU1732800096.USD","LU0689472784.USD","IE000SO60NU8.SGD","IE00BFXG1179.USD","FHLC","IHE","LU0787776722.HKD","LU2213496289.HKD","LU1057294990.SGD","VHT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666257258","title":"美國食品藥品監督管理局（FDA）批准了Scholar Rock公司的一款治療肌肉無力症的藥物","url":"https://stock-news.laohu8.com/highlight/detail?id=2666257258","media":"路透中文","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666257258?lang=zh_tw&edition=fundamental","pubTime":"2026-09-12 05:25","pubTimestamp":1789161915,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）批准了Scholar Rock公司的一款治疗肌肉无力症的药物路透9月11日-美国食品和药物管理局（FDA）周五批准了Scholar Rock公司开发的SRRK.O疗法，用于治疗一种会导致肌肉无力的罕见遗传性疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nL4T4531I4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z9Z06.USD","LU0889565916.HKD","BK4585","BK4532","LU0234570918.USD","LU0320765992.SGD","BK4588","IBRN","BK4533","IE00B19Z9P08.USD","PBE","THNR","LU0109394709.USD","IE00B894F039.SGD","BMED","BK4139","SRRK","BIIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666457170","title":"阿斯利康：SERENA-4臨床試驗未達到主要終點。","url":"https://stock-news.laohu8.com/highlight/detail?id=2666457170","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666457170?lang=zh_tw&edition=fundamental","pubTime":"2026-09-12 04:16","pubTimestamp":1789157801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBQ","PSYK","MDTX","IBBJ","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666576453","title":"美國股市動態","url":"https://stock-news.laohu8.com/highlight/detail?id=2666576453","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666576453?lang=zh_tw&edition=fundamental","pubTime":"2026-09-12 01:49","pubTimestamp":1789148968,"startTime":"0","endTime":"0","summary":".N美国东部时间13:30，道琼斯工业平均指数.DJI上涨1.15%，报52,664.99点。标普500指数.SPX上涨1.07%，报7,673.08点；纳斯达克综合指数.IXIC上涨1.21%，报26,397.44点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nL4S4531CA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GME","WLDR","RJF","FLR","EXEL","RWT","SNDQ","FIZZ","ATO","PMTS","RENT","HPQ","HPE","RKLB","IXG","KR","ADBE","SORCLmain","AGNG","CNAV","KBWB","EW","OKLO","QQQG","SNDK","DLLL","LHSW","BDRX","DELL","ONB","SRFM","STX","CHWY","PANW","TENB","OKLL","ORCL","UCAR","AENT","CIBR","TNON","ACVA","IGV","MRNA","SMR","YARW","CPRT","ADBG","PTF","BMED"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2666544063","title":"興齊眼藥(300573.SZ)：SQ-23082滴眼液獲批開展臨床試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2666544063","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666544063?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 15:54","pubTimestamp":1789113276,"startTime":"0","endTime":"0","summary":"智通财经APP讯，兴齐眼药(300573.SZ)发布公告，近日，公司收到国家药品监督管理局签发的关于SQ-23082滴眼液的《药物临床试验批准通知书》。SQ-23082滴眼液为公司研发的化学药品2.1类改良型新药。临床拟用于过敏性结膜炎相关的眼痒的治疗。根据改良型新药的有关要求，公司已经完成SQ-23082滴眼液药学及非临床药理毒理学等多方面的研究，研究结果表明SQ-23082滴眼液具有良好的安全性及临床开发价值。目前国内外尚无该眼用制剂产品上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494936.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IBBQ","PSYK","IBBJ","BK0177","300573","MDTX","BK0239","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666226544","title":"興齊眼藥：SQ-23082獲臨床試驗批准，屬2.1類","url":"https://stock-news.laohu8.com/highlight/detail?id=2666226544","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666226544?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 15:47","pubTimestamp":1789112862,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBJ","BMED","MDTX","IBBQ","PSYK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666596063","title":"強生（JNJ）漲1.63% 新款雙周拋隱形眼鏡獲CE認證","url":"https://stock-news.laohu8.com/highlight/detail?id=2666596063","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666596063?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 21:21","pubTimestamp":1789046500,"startTime":"0","endTime":"0","summary":"金吾财讯 | 强生（JNJ）美股盘前股价震荡上行，最新涨1.63%，报271.4美元。消息面上，强生周四宣布，旗下新款ACUVUE OASYS MAX双周抛复用隐形眼镜已拿到CE认证。该款产品属于ACUVUE OASYS MAX产品线的新品，可在完整14天佩戴周期内保障佩戴舒适度与清晰视力。镜片搭载OptiBlue滤光技术、TearStable锁泪技术以及一类紫外线防护功能，专门面向长时间使用电子屏幕人群的用眼需求设计。上市节奏方面，计划2026年晚些时候率先登陆部分欧洲国家；后续视各地监管审批进度，在2027-2028年进一步拓展市场。目前该产品尚未取得美国FDA批准，暂未在美国市场销售。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250107/OGNjYWRkOTg0ZTNhODNlYjIwMzU4Nzc5OGE1MjIxNzAyOTY4ODU1OQ==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/OGNjYWRkOTg0ZTNhODNlYjIwMzU4Nzc5OGE1MjIxNzAyOTY4ODU1OQ==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"305910","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BVYPNW00.USD","LU2133065610.SGD","BMED","LU0345770993.USD","BK4581","LU0964807845.USD","JDOC","LU1066053197.SGD","IE000BZT7R73.USD","LU2505996509.AUD","LU1228905037.USD","LU2750360641.GBP","SG9999001440.SGD","XLV","PJP","IHE","TRUH","LU1929549753.HKD","IYH","RXL","LU0820562030.AUD","LU1244550494.USD","LU0345770308.USD","LU1043141396.HKD","IE00BDGV0183.EUR","LU1674673428.USD","IE00BN8TJ469.HKD","LU2750360997.AUD","LU1291159041.SGD","JNJ","LU0124676726.USD","BK4559","LU0689626769.HKD","LU1732800096.USD","VHT","BK4592","FHLC","IE00BLSP4239.USD","LU0070217475.USD","LU0792757196.USD","LU2756315318.SGD","GDOC","FTXH","MEDX","LU2456880835.USD","IE00BGHQF631.EUR","IXJ","LU2756315664.SGD","BK4532","LU0820561909.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666566579","title":"翰宇藥業(300199.SZ)：HY3003注射液臨床試驗申請獲受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2666566579","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666566579?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 16:21","pubTimestamp":1789028518,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰宇药业 发布公告，公司于近日收到国家药品监督管理局核准签发关于HY3003注射液临床试验申请的《受理通知书》。该项目通过人工智能结合多肽芯片技术筛选得到新型多肽分子，由翰宇药业负责临床前研究、IND申报及后续临床试验开发。HY3003拟用于减重、2型糖尿病、代谢相关脂肪性肝炎等适应症，是公司在代谢疾病领域布局的重磅创新药品种。HY3003项目是翰宇药业与碳云智肽在“AI+多肽”领域深度合作的典范。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494391.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BMED","IBBQ","MDTX","BK0188","BK0028","PSYK","BK0239","300199","IBBJ","BK0077","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666456659","title":"默沙東帕博利珠單抗三陰性乳腺癌適應症人群擴展在華獲批","url":"https://stock-news.laohu8.com/highlight/detail?id=2666456659","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666456659?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 16:21","pubTimestamp":1789028510,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["SG9999002224.SGD","IE00B2B36J28.USD","LU2360032135.SGD","HRTS","LU2125909247.SGD","LU1934455194.USD","LU1201861249.SGD","LU1037948541.HKD","SG9999014567.USD","SG9999002232.USD","IE00BLSP4452.SGD","LU2125909593.SGD","LU0320765646.SGD","LU2023250843.SGD","LU1585245621.USD","LU1116320901.HKD","LU2125154778.USD","SG9999014559.SGD","IHE","LU0106261372.USD","LU0124676726.USD","LU0477156953.USD","GDOC","SG9999001440.SGD","LU1989771016.USD","LU1571399168.USD","LU0234572021.USD","LU1983299246.USD","LU0823416689.USD","LU0648001328.SGD","LU0980610538.SGD","LU1116320737.USD","SG9999013999.USD","LU0289739699.SGD","BK4559","IXJ","IYH","LU0208291251.USD","LU1974910355.USD","IE00B1BXHZ80.USD","LU2461242641.AUD","LU0965508806.USD","BK4516","LU0006306889.USD","LU0098860793.USD","LU0965509283.SGD","IE00BN8TJ469.HKD","LU1035773651.USD","LU1699723380.USD","LU2112291526.USD","LU0432979614.USD","IE00B4R5TH58.HKD","BK4588","BK4550","LU0868494708.USD","LU1989772840.SGD","LU2361044865.SGD","LU2023250504.SGD","IE00BJJMRZ35.SGD","LU0211331839.USD","PPH","LU0238689110.USD","IE00BSNM7G36.USD","LU2125154935.USD","LU2324357040.USD","LU0203347892.USD","LU1941712264.USD","IE000M9KFDE8.USD","SG9999015341.SGD","XLV","LU1430594728.SGD","LU1291159041.SGD","LU0965509010.AUD","LU2361044949.HKD","LU0265550359.USD","LU1066051498.USD","LU2357627491.SGD","LU0965509101.SGD","LU0320765489.SGD","LU2433249047.HKD","LU1066051225.USD","LU2468319806.SGD","BK4007","LU1066053197.SGD","IE00BFTCPJ56.SGD","LU1162221912.USD","LU0265550946.USD","IE0002141913.USD","LU2491050154.USD","LU2361045086.USD","LU1934455863.HKD","LU1923622614.USD","SG9999001176.SGD","LU1929549753.HKD","RXL","LU1917777945.USD","LU0058720904.USD","LU2491050071.SGD","SG9999001176.USD","SG9999014575.USD","IE00BJT1NW94.SGD","LU0130517989.USD","LU0868494617.USD","LU1032466523.USD","LU2106854487.HKD","BMED","BK4534","IE00BLSP4239.USD","BK4533","IE0009355771.USD","LU1093756325.SGD","IE00BBT3K403.USD","SG9999014542.SGD","LU1989772923.USD","VHT","LU0859254822.USD","LU1941712348.USD","LU2491049909.HKD","SGXZ57979304.SGD","PAWZ","LU1057294990.SGD","FTXH","LU1093756168.USD","LU2089984988.USD","LU0203345920.USD","LU0266013472.USD","LU1061106388.HKD","JDOC","LU1066051811.HKD","LU1934455277.USD","LU0861579265.USD","TRUH","LU0070302665.USD","LU0130102774.USD","FHLC","LU0985320562.USD","LU1069347547.HKD","MRK","SG9999015358.SGD","LU0689626769.HKD","LU1023059063.AUD","LU0122379950.USD","BK4585","LU0942090050.USD","LU1037948897.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666565044","title":"翰宇藥業：HY3003注射液獲臨床試驗申請受理通知書","url":"https://stock-news.laohu8.com/highlight/detail?id=2666565044","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666565044?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 16:12","pubTimestamp":1789027978,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MDTX","IBBQ","IBBJ","PSYK","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666555270","title":"英硅智能(03696)：公司管線中領先的人工智能驅動候選創新藥物 Rentosertib已在針對特發性肺纖維化的III期臨床試驗中完成首例患者入組","url":"https://stock-news.laohu8.com/highlight/detail?id=2666555270","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666555270?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 08:20","pubTimestamp":1788999632,"startTime":"0","endTime":"0","summary":"智通财经APP讯，英硅智能 发布公告，公司管线中领先的AI驱动候选创新药物 Rentosertib，已于北京协和医院完成III期临床试验的首例患者入组及给药;同日，上海市肺科医院亦完成了其在该试验的首例患者入组。GENESIS-IPF-3为一项评估Rentosertib用于特发性肺纤维化患者的III期临床试验。本试验旨在评估Rentosertib是否能比IIa期研究提供涵盖更大患者群体、且更长时间治疗的临床意义上的获益。Rentosertib透过抑制TNIK，旨在阻断或逆转纤维化进程，为IPF患者提供具备疾病改善潜力的治疗方案。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494199.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["QQQ","GK","03696","QSWN","AQGX","DQJN","NJUL","NJAN","FWD","LCLG","QQQX","AGIX","MDTX","WPAI","PSQ","NOCT","159992","TECY","IBBJ","NBDS","AIFD","161631","QID","CHAT","CWC","LNGR","AIBU","MEDX","AIQU","PSYK","06978","QQA","MVPS","TARK","CPNQ","IBBQ","GPIQ","VUSE","NEWZ","KOMP","ARTY","BMED","QMAR","QTOC","PBOT","TQQY","MFIG","OGIG","TQQQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666580156","title":"拜耳啓動G蛋白偶聯內流整流鉀通道4研究性抑制劑針對心房顫動患者的II期臨床試驗。","url":"https://stock-news.laohu8.com/highlight/detail?id=2666580156","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666580156?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 19:42","pubTimestamp":1788954150,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MDTX","PSYK","IBBQ","BMED","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666584416","title":"Leerink Partners上調默克目標價至161美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2666584416","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666584416?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 18:22","pubTimestamp":1788949320,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["IYH","UDN","LU1934455863.HKD","LU1201861249.SGD","MRK","IHE","SGXZ57979304.SGD","LU1035773651.USD","SG9999015358.SGD","LU1941712264.USD","LU2125909593.SGD","LU0965509283.SGD","LU0234572021.USD","JDOC","FHLC","PAWZ","LU0648001328.SGD","LU0098860793.USD","VHT","LU1066051225.USD","LU2125909247.SGD","LU0203345920.USD","FTXH","LU0965509101.SGD","LU1430594728.SGD","BK4534","LU1923622614.USD","LU2491049909.HKD","PPH","SG9999013999.USD","IE00BJT1NW94.SGD","HRTS","LU2468319806.SGD","UUP","SG9999014567.USD","IXJ","LU0122379950.USD","LU2106854487.HKD","BMED","LU2357627491.SGD","IE00BLSP4239.USD","SG9999014542.SGD","TRUH","LU0980610538.SGD","XLV","LU0689626769.HKD","RXL","GDOC","LU0868494708.USD","LU0238689110.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666846135","title":"石藥集團(01093)：戈舍瑞林緩釋注射液(SYH9102注射液)在中國獲臨床試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2666846135","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666846135?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 18:09","pubTimestamp":1788948562,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团 发布公告，本集团开发的促性腺激素释放激素受体激动剂戈舍瑞林缓释注射液(该产品)已获中国国家药品监督管理局批准，可在中国开展临床试验。该产品为全球首款获批临床的即用型戈舍瑞林缓释注射液，可通过与垂体GnRH受体高亲和力结合并诱导受体降调节，抑制促性腺激素分泌，降低血清睾酮及雌二醇水平，实现药物去势。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493973.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00B5MMRT66.SGD","LU0314109678.HKD","01093","BK1515","IE00BZ08YR35.GBP","LU1226287792.SGD","IE00B031HY20.USD","LU1328277881.USD","PSYK","LU1813983027.USD","SG9999004220.SGD","IE00BZ08YS42.EUR","IE00B543WZ88.USD","IE0008368742.USD","LU1008478684.HKD","LU0326950275.SGD","LU1993786604.SGD","LU0880133367.SGD","LU1226287875.USD","BK1191","LU1152091754.HKD","LU0315179316.USD","LU1807302812.USD","LU1226288253.USD","LU2039709279.SGD","LU0140636845.USD","HK0000165453.HKD","LU1960683339.HKD","BMED","LU1226287529.USD","LU1226288170.HKD","IE00BZ08YT58.USD","BK1521","LU0072913022.USD","LU0067412154.USD","MDTX","IBBQ","KURE","LU1951186391.HKD","LU1152091168.USD","IBBJ","IE0008369823.USD","LU0501845795.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666584690","title":"石藥集團(01093)：戈舍瑞林緩釋注射液(SYH 9102注射液)在中國獲臨床試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2666584690","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666584690?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 18:08","pubTimestamp":1788948523,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团 公布，该集团开发的促性腺激素释放激素受体激动剂戈舍瑞林缓释注射液已获中华人民共和国国家药品监督管理局批准，可在中国开展临床试验。该产品为全球首款获批临床的即用型戈舍瑞林缓释注射液，可通过与垂体GnRH受体高亲和力结合并诱导受体降调节，抑制促性腺激素分泌，降低血清睾酮及雌二醇水平，实现药物去势。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493974.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1813983027.USD","LU1152091168.USD","LU1951186391.HKD","LU2039709279.SGD","LU0314109678.HKD","IBBQ","IE00B5MMRT66.SGD","LU1993786604.SGD","IBBJ","LU1226288253.USD","HK0000165453.HKD","LU1960683339.HKD","LU0067412154.USD","IE00B031HY20.USD","LU1226287875.USD","LU0880133367.SGD","LU0072913022.USD","IE00BZ08YS42.EUR","LU1226288170.HKD","MDTX","LU0140636845.USD","BK1191","LU1328277881.USD","BK1521","LU1152091754.HKD","LU0315179316.USD","LU0501845795.SGD","BK1515","BMED","IE00BZ08YR35.GBP","LU1226287792.SGD","SG9999004220.SGD","LU1807302812.USD","PSYK","IE00B543WZ88.USD","IE0008368742.USD","LU0326950275.SGD","01093","LU1226287529.USD","LU1008478684.HKD","KURE","IE00BZ08YT58.USD","IE0008369823.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":2,"totalSize":200,"code":"91000000","status":"200"}]}}